Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Almost all of the 200 or so approved biopharmaceuticals have been produced in one of three host systems: the bacterium Escherichia coli, yeasts (Saccharomyces cerevisiae, Pichia pastoris) and mammalian cells. We describe the most widely used methods for the expression of recombinant proteins in the cytoplasm or periplasm of E. coli, as well as strategies for secreting the product to the growth medium. Recombinant expression in E. coli influences the cell physiology and triggers a stress response, which has to be considered in process development. Increased expression of a functional protein can be achieved by optimizing the gene, plasmid, host cell, and fermentation process. Relevant properties of two yeast expression systems, S. cerevisiae and P. pastoris, are summarized. Optimization of expression in S. cerevisiae has focused mainly on increasing the secretion, which is otherwise limiting. P. pastoris was recently approved as a host for biopharmaceutical production for the first time. It enables high-level protein production and secretion. Additionally, genetic engineering has resulted in its ability to produce recombinant proteins with humanized glycosylation patterns. Several mammalian cell lines of either rodent or human origin are also used in biopharmaceutical production. Optimization of their expression has focused on clonal selection, interference with epigenetic factors and genetic engineering. Systemic optimization approaches are applied to all cell expression systems. They feature parallel high-throughput techniques, such as DNA microarray, next-generation sequencing and proteomics, and enable simultaneous monitoring of multiple parameters. Systemic approaches, together with technological advances such as disposable bioreactors and microbioreactors, are expected to lead to increased quality and quantity of biopharmaceuticals, as well as to reduced product development times.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Production of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032 · cited 8×
“The viability of cells can be improved by introducing proto-oncogenes and growth factor genes [138].”
BackgroundInfluentialThe genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line
Xu, X., Nagarajan, H., Lewis, N. E., Pan, S., Cai, Z., Liu, X., Chen, W., Xie, M., Wang, W., Hammond, S., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1932 · Cited by 785
Humanization of yeast to produce complex terminally sialylated glycoproteins
Hamilton, S. R., Davidson, R. C., Sethuraman, N., Nett, J. H., Jiang, Y., Rios, S., Bobrowicz, P., Stadheim, T. A., Li, H., Choi, B.-K., et al. (2006) · Science · doi:10.1126/science.1130256 · Cited by 511
Advances in the production of human therapeutic proteins in yeasts and filamentous fungi
Gerngross, T. U. (2004) · Nature Biotechnology · doi:10.1038/nbt1028 · Cited by 409
Choi, B.-K., Bobrowicz, P., Davidson, R. C., Hamilton, S. R., Kung, D. H., Li, H., Miele, R. G., Nett, J. H., Wildt, S., & Gerngross, T. U. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931263100 · Cited by 360
Davies, J., Jiang, L., Pan, L., LaBarre, M. J., Anderson, D., & Reff, M. (2001) · Biotechnology and Bioengineering · doi:10.1002/bit.1119 · Cited by 327 · cited 1×
“Over-expression of 2-b-N-acetylglucosaminyltransferase resulted in incorporation of bisecting N-acetylglucosamine in recombinant antibody, thereby increasing its antibody-dependant cytotoxicity [24].”
BackgroundGlycosylation engineering in yeast: the advent of fully humanized yeast
Hamilton, S. R., & Gerngross, T. U. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.09.001 · Cited by 322 · cited 2×
“The first step in humanization therefore involves the deletion of och1 gene (a-1,6-mannosyltransferase), which is responsible for the transfer of another mannosyl residue to Man8GlcNAc2 intermediate, creating a substrate for further mannosyltransferases [48].”
BackgroundFerrara, C., Brünker, P., Suter, T., Moser, S., Püntener, U., & Umaña, P. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20777 · Cited by 305 · cited 1×
“By changing the localization of 2-b-N-acetylglucosaminyltransferase inside the Golgi, the incorporation of bisecting N-acetylglucosamine was increased [31].”
BackgroundPredicting the Solubility of Recombinant Proteins in Escherichia coli
Wilkinson, D. L., & Harrison, R. G. (1991) · Nature Biotechnology · doi:10.1038/nbt0591-443 · Cited by 250 · cited 1×
“Their formation usually depends on the primary structure of the protein and is connected to the failure to form correct disulphide bonds and to the higher content of hydrophobic regions [83, 136].”
BackgroundIdicula‐Thomas, S., & Balaji, P. V. (2005) · Protein Science · doi:10.1110/ps.041009005 · Cited by 175 · cited 1×
“The ability to predict the formation of inclusion bodies from the protein sequence has advanced, and computer tools have been developed [57, 58].”
BackgroundUnraveling the Chinese hamster ovary cell line transcriptome by next-generation sequencing
Becker, J., Hackl, M., Rupp, O., Jakobi, T., Schneider, J., Szczepanowski, R., Bekel, T., Borth, N., Goesmann, A., Grillari, J., et al. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.09.014 · Cited by 98 · cited 1×
“have already resulted in the determination of a CHO transcriptome [8] and a whole genome [140].”
BackgroundConstruction of engineered CHO strains for high-level production of recombinant proteins
M., K., S., I., Y., F., K., Y., & T., S. (2002) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-002-1134-1 · Cited by 95
Kim, N. S., & Lee, G. M. (2002) · Biotechnology and Bioengineering · doi:10.1002/bit.10191 · Cited by 86
Sensors in Disposable Bioreactors Status and Trends
Glindkamp, A., Riechers, D., Rehbock, C., Hitzmann, B., Scheper, T., & Reardon, K. F. (2009) · Advances in Biochemical Engineering/Biotechnology · doi:10.1007/10_2009_10 · Cited by 65
Engineered mammalian chromosomes in cellular protein production: future prospects
Kennard, M. L. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-61779-099-7_15 · Cited by 10
Cited by
Tripathi, N. K., & Shrivastava, A. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00420 · Cited by 575
Costa, S., Almeida, A., Castro, A., & Domingues, L. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00063 · Cited by 450
Extracellular vesicles as a platform for membrane‐associated therapeutic protein delivery
Yang, Y., Hong, Y., Cho, E., Kim, G. B., & Kim, I. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1440131 · Cited by 258
Microbials for the production of monoclonal antibodies and antibody fragments
Spadiut, O., Capone, S., Krainer, F., Glieder, A., & Herwig, C. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.10.002 · Cited by 258
Fink, M., Vazulka, S., Egger, E., Jarmer, J., Grabherr, R., Cserjan‐Puschmann, M., & Striedner, G. (2019) · Biotechnology Journal · doi:10.1002/biot.201800637 · Cited by 41
Metadata
- Authors
- Berlec, A., & Štrukelj, B.
- Venue
- Journal of Industrial Microbiology and Biotechnology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-04-01
- Volume
- 40
- Issue
- 3-4
- Pages
- 257-274
- ISSN
- 1367-5435 (ISSN-L)
- 1476-5535
- OpenAlex
- W2471180956
- Cited by
- 211
- References
- 15
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.